iPSC-Derived Human Hematopoietic Progenitor Cells with Media

Take advantage of 25% off on these iPSC-derived Cells with Media – offer ends December 31, 2025

Applied StemCell has developed an efficient integration-free, small molecule-based method to differentiate high-quality hematopoietic progenitor cells (HPC) from human iPSCs. The differentiated HPCs recapitulate the phenotype and functional parameters of primary and in vivo HPCs.

We provide HPCs differentiated from an integration-free, control human iPSC line (ASE-9211), reprogrammed from the fibroblasts of an African-American male donor. These high-purity (≥70%) cells express high levels of HPC biomarker, CD34. To harness the full potential of our HPCs, we also provide optimized HPC Culture Basal Media (ASE-9718MM) that supports robust maintenance and functionality of the HPCs in culture.

These iPSC-differentiated HPCs can be used as control lines to compare phenotype and functionality of patient-derived, genome edited iPSC-derived HPCs for drug screening application. These HPCs can also be used as effector cells for cytotoxicity assays.

These iPSC-derived cells are available from the following donors:
– Normal, Male, African American, Neonate, from Fibroblasts (#ASE-9211)
– Normal, Male, Asian, Age 50, from PBMCs

Please contact us for more information.